Akums Drugs & Pharma opens new facility for lyophilized, sterile dosage manufacturing
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products across various therapeutic categories.
New Delhi: Akums Drugs & Pharmaceuticals Ltd. has announced its new state-of-the-art sterile manufacturing facility, dedicated to producing lyophilized products.
In addition to lyophilized injectables, the facility is equipped to manufacture vials, ampoules, Form-Fill-Seal (FFS) products, and eye and ear drops.
"This strategic expansion marks a pivotal step in Akums’ growth journey, significantly enhancing its sterile dosage capabilities. With advanced technology and increased production capacity, the facility positions Akums to meet the rising global demand and support large-scale manufacturing across a wide range of therapeutic areas.
The facility, which is now operational, is equipped with state-of-the-art technology to produce lyophilized (freeze-dried) products across various therapeutic categories. Lyophilization is a crucial process in preserving the stability and shelf life of pharmaceutical products, especially for sensitive chemical compounds.
The global lyophilized injectables market, estimated at a value of approximately USD 3,365.4 million in 2023, is expected to experience steady growth, reaching an impressive USD 4,978.3 million by 2030. With a compound annual growth rate (CAGR) of 5.6% during the forecast period, this market demonstrates strong potential driven by increasing demand for products requiring enhanced stability and extended shelf life. As a niche segment with high entry barriers and limited competition, it presents significant opportunities to innovate and cater to specialized therapeutic needs. This growth highlights the strategic importance of investing in lyophilization capabilities.
“We are excited to announce our entry into lyophilized injectables, marking a significant milestone in our journey to provide world-class pharmaceutical solutions,” said Mr. Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd. “As global demand for lyophilized drugs continues to grow, our new facility is primed to meet this demand with the highest standards of quality and safety.”
“The addition of lyophilization capabilities will enable us to better serve the pharmaceutical industry by offering advanced sterile manufacturing solutions across a range of therapeutic categories,” said Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd. This expansion equips us to cater to a wide range of therapeutic categories with enhanced efficiency.
